<DOC>
	<DOCNO>NCT02058160</DOCNO>
	<brief_summary>Primary Objective : To demonstrate superiority insulin glargine/lixisenatide fix ratio combination ( FRC ) insulin glargine glycated hemoglobin ( HbA1c ) change baseline Week 30 . Secondary Objective : To compare overall efficacy safety insulin glargine/lixisenatide FRC insulin glargine ( without metformin ) 30 week treatment period participant type 2 diabetes .</brief_summary>
	<brief_title>Efficacy Safety Insulin Glargine/Lixisenatide Fixed Ratio Combination Versus Insulin Glargine Patients With Type 2 Diabetes</brief_title>
	<detailed_description>Maximum duration approximately 39 week : 8-week screening period , 30-week randomized treatment period 3 day post-treatment safety follow period .</detailed_description>
	<mesh_term>Diabetes Mellitus</mesh_term>
	<mesh_term>Diabetes Mellitus , Type 2</mesh_term>
	<mesh_term>Insulin , Globin Zinc</mesh_term>
	<mesh_term>Insulin</mesh_term>
	<mesh_term>Metformin</mesh_term>
	<mesh_term>Insulin Glargine</mesh_term>
	<criteria>Inclusion criterion : Type 2 diabetes mellitus diagnose least 1 year screen visit . Treatment basal insulin least 6 month screen visit . Stable basal insulin regimen ( i.e . type insulin time/frequency injection ) least 3 month screen visit . Stable ( plus/minus 20 percent ) total daily basal insulin dose 15 40 Units/day least 2 month prior screen visit . For participant receive basal insulin 1 2 oral antidiabetic drug ( OADs ) : OAD dose ( ) must stable 3 month screen visit . The OADs could 1 2 : metformin ( equal 1500 mg/day maximal tolerate dose ) , sulfonylurea , glinide , dipeptidylpeptidase4 inhibitor , sodium glucose cotransporter 2 inhibitor , Fasting Plasma Glucose ( FPG ) less equal 180 mg/dL ( 10.0 mmol/L ) screen visit participant receive basal insulin combination 2 OADs 1 OAD metformin ; FPG le equal 200 mg/dL ( 11.1 mmol/L ) screen visit participant basal insulin basal insulin plus metformin screening visit . Signed write informed consent . Exclusion criterion : Age legal age adulthood screen visit . HbA1c screen visit le 7.5 % 10 % . Pregnancy lactation , woman childbearing potential effective contraceptive method . Use oral injectable glucoselowering agent state inclusion criterion period 3 month prior screen . Previous use insulin basal insulin eg , prandial premixed insulin , year prior screen . Note : Short term treatment ( â‰¤10 day ) due intercurrent illness allow . History discontinuation previous treatment Glucagon Like Peptide 1 Receptor Agonists safety/tolerability lack efficacy . Participant previously participate clinical trial lixisenatide insulin glargine/lixisenatide FRC previously receive lixisenatide . Use weight loss drug within 3 month prior screen visit . Within last 6 month prior screen visit : history stroke , myocardial infarction , unstable angina , heart failure require hospitalization . Planned coronary , carotid peripheral artery revascularisation procedure perform study period . History pancreatitis ( unless pancreatitis relate gallstone cholecystectomy already perform ) , chronic pancreatitis , pancreatitis previous treatment incretin therapy , pancreatectomy , stomach/gastric surgery . Personal immediate family history medullary thyroid cancer ( MTC ) genetic condition predispose MTC ( eg , multiple endocrine neoplasia syndrome ) . Uncontrolled inadequately control hypertension ( systolic blood pressure 180 mmHg diastolic blood pressure 95 mmHg ) screen visit . At screen visit , Body Mass Index ( BMI ) less equal 20 40 kg/m^2 . At screen visit amylase and/or lipase 3 time upper limit normal ( ULN ) laboratory range . At screen visit alanine aminotransferase ( ALT ) alkaline phosphatase ( AST ) 3 ULN . At screen visit calcitonin equal 20 pg/mL ( 5.9 pmol/L ) . Any contraindication metformin use , accord local labeling , participant take metformin . Participant renal function impairment creatinine clearance le 30 mL/min ( use Cockcroft Gault formula ) endstage renal disease participant , treat metformin . Exclusion criterion randomization : HbA1c le 7 % 10 % . Mean fast SMPG calculate selfmeasurements 7 day week randomization visit 140 mg/dL ( 7.8 mmol/L ) . Average insulin glargine daily dose less 20 Units 50 Units ( week randomization visit ) . Amylase and/or lipase 3 ULN . The information intend contain consideration relevant participant 's potential participation clinical trial .</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>December 2016</verification_date>
</DOC>